Ignite Creation Date:
2024-05-05 @ 9:05 PM
Last Modification Date:
2024-10-26 @ 9:59 AM
Study NCT ID:
NCT00809328
Status:
COMPLETED
Last Update Posted:
2011-05-19
First Post:
2008-12-16
Brief Title:
The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia CAP
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Multicenter Non-Randomized Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Community Acquired Pneumonia CAP Requiring Initial Intravenous Therapy
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Azithromycin has high rates of clinical response and eradication wide spectrum of activity so we suppose the development of the azithromycin injectable formulation in Japan would deliver benefit to patients of community acquired pneumonia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None